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OBJECTIVE: To estimate the prevalence of hepatitis C virus infection in 
Brazil’s inmate population . 
METHODS: Systematic review on hepatitis C virus infection in the inmate 
population. Brazilian studies published from January 1, 1989 to February 
20, 2014 were evaluated. The methodological quality of the studies was 
assessed using a scale of 0 to 8 points.
RESULTS: Eleven eligible studies were analyzed and provided data on 
hepatitis C virus infection among 4,375 inmates from seven states of Brazil, 
with a mean quality classification of 7.4. The overall hepatitis C virus 
prevalence among Brazilian inmates was 13.6% (ranging from 1.0% to 
41.0%, depending on the study). The chances of inmates being seropositive 
for hepatitis C virus in the states of Minas Gerais (MG), Sergipe (SE), Mato 
Grosso do Sul (MS), Rio Grande do Sul (RS), Goiás (GO) and Espirito Santo 
(ES) were 84.0% (95%CI 0.06;0.45), 92.0% (95%CI 0.04;0.13), 88.0% 
(95%CI 0.09;0.18), 74.0% (95%CI 0.16;0.42), 84.0% (95%CI 0.08;0.31) 
and 89.0% (95%CI 0.01;0.05) respectively, lower than that observed in the 
Sao Paulo state (seroprevalence of 29.3%). The four studies conducted in 
the city of Sao Paulo revealed a lower prevalence in more recent studies 
compared to older ones. 
CONCLUSIONS: The highest prevalence of hepatitis C virus infection 
in Brazil’s inmate population was found in Sao Paulo, which may reflect 
the urban diversity of the country. Despite Brazilian studies having good 
methodological quality to evaluate the prevalence of the hepatitis C virus, 
they are scarce and lack data on risk factors associated with this infection, 
which could support decisions on prevention and implementation of public 
health policies for Brazilian prisons.
DESCRIPTORS: Prisoners. Hepacivirus. Prevalence. Hepatitis C, 
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Hepatitis C virus (HCV) infection is a major worldwide 
health care problem. The World Health Organization esti-
mates that approximately 150 million people are chron-
ically infected with HCV, and more than 350,000 people 
die every year from hepatitis C-related liver diseases.a 
The disease severity ranges from a mild illness lasting a 
few weeks to a serious lifelong condition in almost 85.0% 
of cases, which can lead to liver cirrhosis or liver cancer. 
Patients can remain symptom-free for a long time; for 
example, liver disease may appear up to 20 or 30 years 
after the initial infection.23
HCV is transmitted by contact with the blood of 
an infected person. Although several transmission 
mechanisms are known, such as injection drug use, 
tattooing, sexual intercourse, invasive medical or 
dental procedures, and perinatal transmission, other 
routes remain unknown.37
The population confined in prisons may have a higher 
prevalence of HCV than the general population due 
to its low socioeconomic level and high prevalence of 
injecting drug dependence. The environment in most 
prisons could also contribute to local transmission. 
People confined in prisons are more likely to engage in 
high-risk behaviors for HCV infection than the general 
population,38 and the serving time in prison increases 
risk exposures to other prisoners, because they usually 
have poor access to health care and live in poverty. This 
exposure may include high-risk sexual practices, such 
as sexual intercourse with prisoners with a history of 
sexually transmitted diseases (STD) or with a former 
or current injection drug user.38,45 However, incarcera-
tion conditions and the high cost of conducting research 
hamper a prospective evaluation of the extent of HCV 
spread within prisons. Few studies have addressed this 
issue with a prospective follow-up. In 2010, a study 
conducted among injecting drug-using inmates from 
Australia evaluated the reinfection of different HCV 
genotypes and showed that the incidence of HCV infec-
tion was 40/100 person-years.31 In Brazil, Gois et al15 
have argued that prisoner health has become a public 
health problem.
The prevalence of HCV infection in prisons varies by 
country: 5.0% in Venezuela,29 15.2% in Pakistan,21 
19.0% in Scotland,43 12.0%-31.0% in the United 
States,42 34.1% in Indonesia34 and 46.0% in Norway.20 
The reason for the difference in results may be vari-
ations in the design, aims and criteria of different 
studies. Most studies around the world are conducted 
INTRODUCTION
among male inmate populations, probably because 
they are larger than female ones. In 2012, Brazil had 
512,964 male inmates and only 35,039 female inmates.b 
Furthermore, the choice of anti-HCV screening tests 
can also influence the variation in prevalence among 
countries, as well as in the general population. More 
accurate assays, such as molecular testing for HCV 
RNA detection, can be used for confirmation.9 Another 
important factor is whether the survey was performed 
among inmates entering prison or among already incar-
cerated inmates, who may have been more exposed to 
STD and drug use, increasing the chance of intra-prison 
transmission of HCV. The proportion of inmates that 
are injecting drug users (IDU) is very relevant informa-
tion, as well as the number of inmates with tattoos.38,45
The aim of this study was to estimate the prevalence 
of HCV infection among Brazil’s inmate population.
METHODS
This systematic review was based on the directions of 
Stroup et al41 and Moher et al.28
The search included articles from January 1, 1989 
until February 20, 2014, using the PubMed (Medline), 
Lilacs and Embase databases. No language restriction 
was used. The terms for the search were (hepatitis C 
OR HCV) AND (prisoners OR inmates) AND Brazil* 
in all databases. Multiple reports of the same study 
were identified as duplicates and counted as one study.
In an attempt to identify other relevant studies, refer-
ences from articles obtained in the database searches 
and from review articles about the topic were manu-
ally researched.
We included studies: reporting primary data; conducted 
in prisons in Brazil; that conducted biological testing 
to detect antibodies against HCV (anti-HCV); and that 
evaluated prisoners aged 18 years or older. The exclu-
sion criteria were: evidence that the study population 
was not in fact prisoners; studies of subpopulations 
within the inmates; studies with a sample size smaller 
than 50 individuals; case reports and case series; and 
studies that failed to present data clearly enough. 
Reviews of the literature were excluded, but the data 
reported were checked and compared with the results 
of the present study.
First, the titles and abstracts were screened for relevance 
independently by two of the investigators (MCM and 
a World Health Organization. Hepatitis C: updated 2014. Geneva; 2014 [cited 2014 Feb 16]. (Fact sheet, 164). Available from: http://www.
who.int/mediacentre/factsheets/fs164/en/ 
b Ministério da Justiça, Departamento Penitenciário Nacional – DEPEN. Sistema Nacional de Informação Penitenciária – InfoPen: estatística. 
Brasília (DF); 2012 [cited 2014 May 21]. Available from: http://portal.mj.gov.br/main.asp?View={D574E9CE-3C7D-437A-A5B6-22166AD2E89
6}&Team=&params=itemID={2627128E-D69E-45C6-8198-CAE6815E88D0};&UIPartUID={2868BA3C-1C72-4347-BE11-A26F70F4CB26}
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WPP or KYI). Second, disagreements were resolved 
by discussion. Third, the full text of all articles deemed 
relevant were screened. Finally, all full articles were 
read by at least two investigators (MCM and WPP or 
FMT), and whenever there was any disagreement, it 
was read by a third investigator and discussed.
We extracted the following information from each 
study: first author, year of publication, city and state, 
the year in which it was conducted, sex and age of 
participants, laboratory methods used in anti-HCV 
detection, sample size and number of participants 
positive for anti-HCV. To assess the quality of the 
studies, we created a quality assessment scale (0 to 8 
points) based on the criteria proposed by Boyle8 and 
Fowkes and Fulton.14 The scale includes reporting 
study design, inclusion and exclusion criteria, compli-
ance with established criteria, outcome definition and 
measurement, total number of participants, proportion 
of non-respondents, and number of outcome events. A 
higher score indicates better quality.
The methods used for anti-HCV detection were 
enzyme-linked immunosorbent assay (ELISA) of any 
generation and other immunoassay tests. They are 
listed in Table 1, and we consider the tests appropriate 
for this aim.
Data used for the analysis were extracted from the 
eligible studies included in this review. Chi-square 
tests, odds ratios (OR) and 95% confidence intervals 
(95%CI) were calculated using logistic regression and 
the software SPSS, version 20.0.
RESULTS
Using the initial literature search strategies, we identi-
fied 50 studies, including 25 duplicates. After reading 
the abstracts, 11 were excluded. Thus, the full texts 
of 14 articles were reviewed, all of them available in 
English, and three of them were excluded (Figure). 
The studies by Fialho et al13 and Zanetta et al48 were 
excluded in full text review because they included 
inmates younger than 18 years of age. The study by 
Strazza et al39 from 2004 was excluded because it 
included samples from the same prison as the study 
by Strazza et al40 from 2007, which provided detailed 
information and therefore was included.
Finally, 11 studies were included in the present review, 
and their mean quality classification was 7.4 (ranging 
from 5 to 8) (Table 2).
The number of inmates reported in the included studies 
ranged from 63 to 756. Overall, these studies included 
4,375 inmates from seven different Brazilian states and 
were conducted between 1993 and 2011. Four studies 
included only male prisons, three included female 
prisons and four included both male and female prisons. 
Inmates were aged 18 to 80 years.
The prevalence of HCV infection in Brazilian inmates 
in all the studies was determined by the presence of 
anti-HCV in the blood, and the mean prevalence was 
13.6%, with the lowest prevalence detected in the state 
of Espirito Santo (1.0%) and the highest in the state of 
Sao Paulo (41.0%) (Table 1).
Table 3 shows the prevalence of HCV (with confi-
dence intervals) among inmate populations grouped 
into the seven Brazilian states included in this system-
atic review. Furthermore, it presents a comparison of 
means between Sao Paulo (reference category) and the 
other states. The chances of inmates being seropositive 
for HCV in the states of Minas Gerais, Sergipe, Mato 
Grosso do Sul, Rio Grande do Sul, Goias and Espirito 
Santo were 84.0%, 92.0%, 88.0%, 74.0%, 84.0% and 
89.0% lower, respectively, than in Sao Paulo state.
Table 4 shows the prevalence with confidence intervals 
from the four studies conducted in the state capital, the 
city of Sao Paulo, and a comparison of the means from 
the first and the last studies conducted there. The results 
indicate that the prevalence reported in later studies 
was lower than that in the earlier ones. The chance of 
inmates being seropositive for HCV in Sao Paulo State 
in the years of 1997 and 2000 was 72.0% and 75.0% 
lower, respectively, than in 1993-1994.
DISCUSSION
The mean prevalence of HCV in Brazilian inmates in 
the present systematic review was 13.6%, ranging from 
1.0% to 41.0%, with the lowest prevalence detected in 
the state of Espirito Santo and the highest in the state 
of Sao Paulo. With at least 550,000 people detained in 
Brazilian prisons,b we can consider that there might 
be 74,800 inmates with hepatitis C in Brazil. There 
are few studies available in Latin American countries 
regarding the prevalence of HCV among inmates. A 
study carried out in Mexico found a prevalence of 
10.0%,4 and another one in Venezuela found a preva-
lence of 5.0%.29 Worldwide, the prevalence rates vary 
significantly: 4.9% in France,44 8.1% in Iran,5 16.6% in 
Canada,33 19.2% in Ghana,3 21.8% in Ireland,25 24.2% 
in England,22 38.0% in Italy,6 46.0% in Norway20 and 
57.5% in Australia.19
The present review indicates that the city of Sao Paulo 
has reported the highest prevalence of HCV infection, 
with a mean prevalence of 27.6% (ranging from 16.2% 
to 41.0%).18,26,27,40 This may be explained by the urban 
diversity of the country. Sao Paulo is considered one 
of the most populous cities in the world and is one of 
the main destinations for migrants from other cities 
of Brazil.
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The study that reported the highest prevalence, 41.0%, 
was conducted in Sao Paulo, in the Carandiru prison. 
According to the authors, it was one of the clusters of 
highest reported HCV infection, and it remains so in 
Brazil until today. The authors believed that most of 
the HCV infections occurred prior to imprisonment.18 
It is important to emphasize that Carandiru was huge. 
There were nine blocks divided into several prison cells 
according to the features of the crime committed. We 
do not know the exact election criteria for the inmates/
blocks included in the study. Of note, Carandiru 
complex was deactivated and partially demolished 
in 2002.
The studies involved 4,375 inmates in the last 20 years 
(1993-2013). The first selected study was conducted 
in 1993. At that time, there was no standard mecha-
nism for consolidating data on the Brazilian inmate 
population; concrete data have been available at the 
Brazilian Ministry of Justice website since 2000. In 
2000, there were 139,188 inmates in closed regime 
in Brazil, whereas in December 2011, the year when 
the last study was performed, that number increased 
to 203,446.b Therefore, the prevalence of HCV infec-
tion in this population may have been underestimated. 
Indeed, the latest (December 2012) statistics available 
at the Ministry of Justice website about the total inmate 
population regime shows 548,003 inmates, which is 
among the largest in the world.b
The scale used to assess the quality of the studies 
was considered appropriate, and the mean quality 
classification was 7.4 (the lowest score was 5), indi-
cating that the articles included in the analysis were 
of good quality.
Our study has some limitations, such as the validity 
of the laboratory tests. Most anti-HCV screening tests 
use the ELISA technique because of its high sensi-
tivity and specificity, ease manipulation, and low cost, 
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Figure. Flowchart of study selection in the different phases of the systematic review.
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besides considerable improvement over the years. 
Second- and third-generation ELISA have accept-
able accuracy and thereby can help reduce the need 
for polymerase chain reaction (PCR)-based labora-
tory screening.24 Diagnostic methods for detecting 
anti-HCV in the literature have shown differences 
among the first three generations of ELISA. They found 
70.0%-80.0%, 92.0%-95.0%, and 97.0% sensitivity 
in first-, second- and third-generation ELISA, respec-
tively.9 A study conducted in Brazil suggested a strong 
correlation between second-generation anti-HCV 
ELISA and HCV RNA positivity by PCR.16 Another 
study published in the late 2000s about laboratory 
testing for hepatitis C reported that anti-HCV antibodies 
are usually detected using third- or fourth-generation 
immunoenzymatic assays that contain HCV core anti-
gens and HCV nonstructural genes.17
In the present systematic review, the studies of 
Massad et al26 and Guimarães et al18 were conducted in 
1993 and 1994. The first one used second-generation 
ELISA and the other, third-generation ELISA. The other 
studies are from later years,7,10-12,27,32,35,36,40 when it was 
possible to access second- and third-generation kits. 
The articles that described the generation or version 
of the kit and used the third-generation kit are shown 
in Table 1.12,18,32,40 The second- and third-generation 
ELISA tests have a specificity of approximately 99.0%, 
so the chance of false-positive results is generally 
considered not significant. Five studies performed 
confirmatory tests, four of them with in-house molec-
ular testing (presence of virus), and the percentages 
of confirmed positive cases were 100%,12 94.5%,26 
91.7%,36 69.0%,32 and 55.5%7 (Table 1). This raises 
questions about false-positive results in serology 
and possible difficulties in molecular testing, such as 
detecting a phase of low viremia or seroconversion, the 
high cost of supplemental tests for diagnosing HCV 
infection and the need for adequate laboratory infra-
structure. This issue is still relevant and somewhat 
controversial; some authors believe that even a speci-
ficity of 99.0% does not provide the desired predictive 
value for a positive test, especially among populations 
with a low prevalence of HCV infection and popula-
tions without liver-related diseases30,47 such as inmates. 
Therefore, a number of false-positives by anti-HCV 
detection could have been present in the analyzed data, 
possibly constituting a study limitation.
As a second limitation, most studies used convenience 
sampling of inmates at the institutions. Thus, it is 
possible that the relevant characteristics of this group 
do not represent those of the total population. We found 
only one article on this topic in prisons in Northeastern 
Brazil,36 and none in Northern region. We do not know 
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Brazilian prisons are suffering from overcrowding 
and, worsening the situation, prisoner mobility within 
the prison system and contact with the external popu-
lation (conjugal visits) might increase the chances 
of exposure to other individuals infected with HCV 
or other STD. In general, STD prevalence is higher 
among inmate populations than in the general popu-
lation also because they might engage in high-risk 
sexual practices.38 In addition, many prisoners use 
illicit drugs, including injectable ones. The propor-
tion of current or former IDU is approximately 40.0% 
of the prison population in many countries.46 IDU 
have been considered the main segment infected 
with HCV in most of the world.2 A meta-analysis 
of the risk factors associated with HCV prevalence 
in Brazilian prisons was not feasible because most 
studies did not analyze the risk factors for HCV 
infection, but we believe that the use of injectable 
drugs favors virus transmission through the blood 
of the users.
Currently the number of IDU in Brazil is apparently 
decreasing due to the increased number of crack 
cocaine users (crack cocaine is smoked),1,c which 
appears to be associated with its low cost and plea-
surable effects.d Actions to prevent drug use within 
the prison system should be implemented; however, 
the acceptability of drugs and their availability 
within prisons are obstacles to these interventions. 
Furthermore, prevention and health training programs 
may also be important, for example workshops on 
drugs for inmates, psychological care and production 
of informative materials for prisoners and their fami-
lies. In summary, it is important to think about the 
implementation of public policies and policy consist-
ency in public health because these inmates are often 
confined in extremely unhealthy conditions.
Also, tattooing and body piercing, both prior to or while 
incarcerated, may affect HCV prevalence. In addition, 
blood-to-blood contact as a result of violence between 
inmates should also be analyzed and considered as a 
possible risk factor in future studies.
Although some progress has been made over the 
last decades, studies to date are scarce and prob-
ably do not reflect the reality of Brazilian prisons. 
Voluntary testing to detect HCV could be provided, 
along with necessary information about the infection 
in the case of a positive test. Specific treatment for 
hepatitis C should be available with the persistent 
aim of obtaining a sustained virologic response. 














Lower Upper Lower Upper
Massad et al26 (1999) 1993-1994 215 631 34.1 30.4 37.8 Ref. < 0.001
Guimarães et al18 (2001) 1993-1994 310 756 41.0 37.5 44.5 1.35 1.08 1.68
Miranda et al27 (2000) 1997 23 121 19.0 12.0 26.0 0.45 0.28 0.74
Strazza et al40 (2007) 2000 47 290 16.2 12.0 20.4 0.37 0.26 0.53  
Ref.: Reference category (based on the year of sample collection)












Lower Upper Lower Upper
Sao Paulo 624 2,131 29.3 27.3 31.2 Ref. – – < 0.001
Minas Gerais 4 63 6.3 0.3 12.4 0.16 0.06 0.45
Sergipe 13 422 3.1 1.4 4.7 0.08 0.04 0.13
Mato Grosso do Sul 33 686 4.8 3.2 6.4 0.12 0.09 0.18
Rio Grande do Sul 19 195 9.7 5.6 13.9 0.26 0.16 0.42
Goias 9 148 6.1 2.2 9.9 0.16 0.08 0.31
Espirito Santo 7 730 1.0 0.3 1.7 0.02 0.01 0.05
Total 709 4,375 16.2 15.1 17.3 – – –
Ref.: Reference category (based on the highest seroprevalence – Sao Paulo)
c United Nations Office on Drugs and Crime – UNODC. World Drug report 2012. Vienna; 2012 [cited 2015 Feb 16]. Available from: 
https://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf 
d Ministério da Saúde. Coordenação Nacional de Saúde Mental, Álcool e Outras Drogas. O crack: como lidar com este grave problema. 
Brasília (DF); 2009. 
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Further studies to better understand inmate risks 
are needed to control the spread of HCV infection 
in Brazilian prisons and to make ideal treatment and 
prevention decisions.
Finally, the prevalence of hepatitis C and STD in 
Brazilian prisons needs to be considered a consequence 
not only of the limited care provided to inmates but also 
of the increasing incarceration rates in Brazil.
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